The Rhode Island Vaccine Assessment Program was formed in 2015 to assist the State of Rhode Island in purchasing vaccines for children and adults at more equitable rates. RIVAP assures the necessary flow of vaccine purchase funds by collecting payments from health plans, insurance companies, and other payers and remitting the funds to the state. Through the state's Immunization Fund, the state purchases vaccines at favorable rates and distributes them to providers at no charge.
Why Universal Vaccine Purchase?
There are several reasons that the state pushed to promote the universal purchase of vaccines:
Lower Costs: States that serve as the single purchaser of vaccines receive more favorable pricing. Depending on the vaccine, these prices range from an estimated 15 percent to 60 percent lower than private purchase alternatives. These savings lower the costs of health care and, ultimately, help hold down rising premium costs for individuals and benefit costs for employers.
For more information
Provider Benefits and Family Choice: Health care providers continue to administer vaccines to their patients, free of worry. In addition, they avoid the financial and staffing burden required to purchase vaccines privately and both store and administer serum separately for privately and publicly insured children and adults. Additionally, as vaccine purchases are uncoupled from tight state budgetary controls generally, families and physicians gain access to a wider range of federally approved vaccines affording them a wider range of therapeutic choices.
Immunization Benefits: Next to clean drinking water and good nutrition, vaccines have saved more lives than any other public-health intervention in modern history. The Centers for Disease Control estimates that vaccinating every child born in the U.S. from birth to adolescence would prevent 14 million infections, spare 33,000 lives, and save $10 billion in medical costs. (Source: “How Safe Are Vaccines?” by Alice Park, Time, May 21, 2008.)
For more information about the role and progress of the RIVAP, please email us at email@example.com.